RxDoctor Payments Data

Neal Moore, DO

Family Medicine · Kansas City, MONPI 1134129489

Payments from drug & device makers

$14,157in general payments, 2019–2025

Across 940 payments — averaging $15.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • Novo Nordisk$1K
  • Abbott$827
  • plus $7K from 46 others

What the payments were for

  • Food & beverage$14,107100%
  • Other$500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,157 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$69,335
Medicare patients
219
Services billed
1,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$69,709
OzempicSemaglutide51$51,273
MounjaroTirzepatide40$49,022
JardianceEmpagliflozin25$30,053
FarxigaDapagliflozin Propanediol26$20,610
JanuviaSitagliptin Phosphate23$17,902
Tresiba Flextouch U-200Insulin Degludec15$17,002
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$15,082
MyrbetriqMirabegron22$13,683
Nurtec OdtRimegepant Sulfate11$11,055
GlyxambiEmpagliflozin/Linagliptin15$9,807
VascepaIcosapent Ethyl15$8,881
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$7,750
Novolog FlexpenInsulin Aspart23$7,317
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$6,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt, Abrysvo, Paxlovid$1,202$86,173119 claims
Novo NordiskOzempic$1,114$51,27351 claims
Lilly USA, LLCMounjaro$1,307$49,02240 claims
Boehringer IngelheimJardiance, Glyxambi$485$39,86040 claims
AstraZenecaFarxiga$1,589$20,61026 claims
MerckJanuvia$203$17,90223 claims
Astellas Pharma US IncMyrbetriq$370$13,68322 claims
GSKShingrix$385$2,83013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →